As PCFT becomes active in more acidic tumor environment, new generations of 6-substituted pyrrolopyrimidine compounds with selective PCFT-mediated transport and effective in malignant mesothelioma and non-small cell lung cancer is under development [144]. This evidence concerns the gene SLC46A1 and neoplasm.